NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Actavis may buy Allergan for at least $60 billion - Bloomberg

Published 12/11/2014, 20:07
Actavis may buy Allergan for at least $60 billion - Bloomberg
AGN
-
AGN_pa
-
BHC
-

(Reuters) - Merger talks between Allergan Inc (N:AGN) and white knight Actavis Plc (N:ACT) are focussed on narrowing a gap of about $3 billion (1.90 billion pounds) between what has been offered and what is wanted, Bloomberg reported on Wednesday.

Actavis is willing to pay around $200 per share, or $60 billion, while Allergan wants more than $210 per share, Bloomberg said.

Actavis and Allergan declined to comment.

Allergan is trying to fend off a hostile takeover by Canadian drugmaker Valeant Pharmaceuticals International Inc (TO:VRX) (N:VRX), which has offered about $54 billion in cash and stock for the company, but has said it is prepared to raise that to $200 per share.

Allergan said last week it was in talks with a second bidder, and sources familiar with the situation said the company was Actavis.

Separately, Allergan on Wednesday changed its bylaws on calling a special shareholder meeting. The move comes ahead of a special meeting at which shareholders will vote on a proposal by activist investor William Ackman, who wants a rule change allowing the investors who requested the gathering to set the date for it.

Changing the bylaws is just one of the proxy proposals made by Ackman, who also wants to remove board members and compel Allergan into takeover talks.

The amended laws now include a provision that requires Allergan's board to call for a meeting within 90 days of a valid request rather than exercise its discretion, Allergan said.

The company also reduced the amount of information required from someone calling for a special meeting, and eliminated a requirement to disclose who is acting in concert with the shareholder making the proposal.

Ackman and proxy advisory firms pressured Allergan to change these rules, saying they were too onerous.

© Reuters. Allergan CEO Pyott speaks during an interview in New York

Allergan shares were up 46 cents at $195.80 in afternoon trading, while Valeant was $1.07 higher at $131.10, both on the New York Stock Exchange.

(Reporting by Caroline Humer in New York and Natalie Grover in Bangalore; Editing by Saumyadeb Chakrabarty and Andre Grenon)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.